Genmab A/S Sponsored ADR $GMAB Stock Holdings Increased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership boosted its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 36.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 4,978,058 shares of the company’s stock after buying an additional 1,334,919 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Genmab A/S were worth $153,324,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Terra Nova Asset Management LLC bought a new position in shares of Genmab A/S during the fourth quarter valued at approximately $1,866,000. Perpetual Ltd bought a new position in shares of Genmab A/S during the fourth quarter valued at approximately $25,478,000. Assetmark Inc. grew its holdings in shares of Genmab A/S by 2,423.8% during the fourth quarter. Assetmark Inc. now owns 233,852 shares of the company’s stock valued at $7,203,000 after purchasing an additional 224,586 shares during the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Genmab A/S during the fourth quarter valued at approximately $1,331,000. Finally, Alliancebernstein L.P. grew its holdings in shares of Genmab A/S by 2.7% during the third quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock valued at $335,957,000 after purchasing an additional 291,538 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GMAB has been the subject of several recent research reports. Truist Financial initiated coverage on Genmab A/S in a report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price for the company. Jefferies Financial Group began coverage on Genmab A/S in a research report on Tuesday, February 17th. They set a “buy” rating and a $41.50 price objective for the company. Wolfe Research began coverage on Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective for the company. Weiss Ratings downgraded Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Finally, The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.93.

Genmab A/S Stock Performance

GMAB opened at $24.58 on Tuesday. The business has a fifty day simple moving average of $26.71 and a 200-day simple moving average of $29.18. The firm has a market cap of $15.33 billion, a PE ratio of 18.62, a P/E/G ratio of 1.49 and a beta of 0.85. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. Genmab A/S Sponsored ADR has a fifty-two week low of $20.23 and a fifty-two week high of $35.43.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.